Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement

Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.

Annelie Skafte Persson, Cellectricon's Chief Executive Officer, said, "Cellectricon invents and develops advanced cell-based microfluidic screening solutions for applications in drug discovery and basic research. Cellectricon has an extensive intellectual property portfolio with novel cell-based screening technologies based on fifteen years of world-renowned research. To ensure a fair return on our research and development efforts we must protect our intellectual property and we will take all necessary steps to prevent its unauthorized use."

Cellectricon's Chairman Lars-Eric Utterman added, "Cellectricon is a highly innovative company which has successfully launched several advanced screening systems on the life science market. Today's litigation is a strategic step to defend Cellectricon's intellectual property from being infringed."

Source:

CELLECTRICON AB

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Fluxion Biosciences. (2019, June 19). Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement. News-Medical. Retrieved on June 20, 2024 from https://www.news-medical.net/news/20100202/Cellectricon-resumes-litigation-against-Fluxion-Biosciences-over-alleged-patent-infringement.aspx.

  • MLA

    Fluxion Biosciences. "Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement". News-Medical. 20 June 2024. <https://www.news-medical.net/news/20100202/Cellectricon-resumes-litigation-against-Fluxion-Biosciences-over-alleged-patent-infringement.aspx>.

  • Chicago

    Fluxion Biosciences. "Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement". News-Medical. https://www.news-medical.net/news/20100202/Cellectricon-resumes-litigation-against-Fluxion-Biosciences-over-alleged-patent-infringement.aspx. (accessed June 20, 2024).

  • Harvard

    Fluxion Biosciences. 2019. Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement. News-Medical, viewed 20 June 2024, https://www.news-medical.net/news/20100202/Cellectricon-resumes-litigation-against-Fluxion-Biosciences-over-alleged-patent-infringement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Automated CTC analysis isoflux cytation imager launched by Fluxion Biosciences